Rx / Prescription Volume
GLP-1 prescription volume accelerating as insurance coverage expands.
Why GLP-1 Matters Here
This vertical tracks the root cause. GLP-1 prescription volume is the leading indicator for every behavioral shift ImpulseIndex measures across other verticals.
The adoption curve has two primary drivers running simultaneously: clinical evidence accumulation (cardiovascular outcome data from SURMOUNT-MMO and SELECT trials has materially expanded prescriber confidence beyond weight loss alone) and insurance coverage expansion (Medicare Part D coverage of Wegovy for cardiovascular risk reduction, effective 2024, opened a previously blocked patient population).
What the Data Shows
KFF polling found 1 in 8 US adults currently taking a GLP-1 medication as of November 2025, roughly double the rate from eighteen months earlier. FAIR Health's analysis of 51 billion commercial claims documents a 364 percent relative increase in prescriptions from 2019 to 2024.
Analysis
The rate of adoption, not the current level, is what makes this the right leading indicator.
Recent Coverage
Research Findings
Curated citations from peer-reviewed studies and institutional research
Percentage of adult patients prescribed any GLP-1 drug increased from 0.9% in 2019 to 4.0% in 2024, a 364% relative increase
% relative increase in GLP-1 prescriptions 2019 to 2024
Approximately 1 in 8 U.S. adults currently taking a GLP-1 medication as of November 2025
% of U.S. adults currently taking a GLP-1 medication
Industry Fundamentals
Medicare Part D Claims
Data Sources
Two-layer architecture: government fundamentals + curated research
Industry Fundamentals
Updated 2 days agoMedicare Part D Claims
Research Citations
FAIR Health, KFF
Peer-reviewed studies, investment bank analysis, and institutional surveys. Manually curated and updated monthly.
Get updates on Rx / Prescription Volume
Monthly data updates when this vertical's citations and industry data change.